Pregnancy-associated extracorporeal life support: insights from a nationwide dual-cohort analysis.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42624670.
- Also identified by DOI 10.1016/j.bja.2026.07.015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Extracorporeal life support (ECLS) is used as rescue therapy for refractory cardiopulmonary failure. Population-level evidence on prognosis and long-term sequelae in patients requiring ECLS during pregnancy or the peripartum period remains limited. We performed a nationwide retrospective dual-cohort study using linked Taiwanese databases (2001-22). In the delivery cohort, 247 ECLS pregnancies were compared with 3 970 948 non-ECLS pregnancies. In the ECLS cohort, 247 pregnancy-associated ECLS cases were compared with 2112 non-pregnant women of reproductive age receiving ECLS. Outcomes included 42-day maternal mortality and complications, neonatal outcomes, and long-term maternal outcomes beyond 42 days postpartum. The incidence of pregnancy-associated ECLS was 6.2 per 100 000 deliveries and increased over time (P trend <0.001). Leading indications were amniotic fluid embolism (26.7%), peripartum cardiomyopathy (18.6%), and respiratory failure (12.6%), with highest mortality in obstetric indications. Maternal mortality at 42 days was 41.3%, with renal failure (36.4%), major bleeding (11.3%) and stroke (10.9%) as major morbidities. Neonates had higher risks of preterm birth, low birth weight, and major morbidity. Beyond 42 days postpartum, ECLS-exposed pregnant patients had higher all-cause mortality (adjusted hazard ratio [aHR] 28.0, 95% confidence interval [CI] 16.8-46.8), cardiovascular mortality, permanent dialysis, and psychiatric disorders. In the ECLS cohort, pregnancy-associated ECLS had lower in-hospital mortality (43.7% vs 53.8%) and better long-term survival (aHR 0.42, 95% CI 0.23-0.78) than nonpregnant recipients. Pregnancy-associated ECLS is rare but is increasing in incidence, and identifies a clinically high-risk population with substantial early maternal and neonatal risk. Multidisciplinary follow-up is required for survivors of pregnancy-associated ECLS in view of their ongoing risk of long-term cardiovascular, renal, and psychiatric sequelae.